Mode
Text Size
Log in / Sign up

Granulomatosis with polyangiitis

Part of Interstitial Lung Disease

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Granulomatosis with polyangiitis

3 trials tracked for Granulomatosis with polyangiitis: 1 in phase 3 or 4.

3Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 2 1 Other / NA 1
  1. Phase 4 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed
  2. Phase 2 A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed
  3. N/A An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Granulomatosis with polyangiitis

Are patients with granulomatosis with polyangiitis at higher risk for cardiovascular events?

Patients with granulomatosis with polyangiitis face a significantly higher risk of cardiovascular events like heart attacks and strokes compared to the general population.

Full answer →